CCA
NRIX icon

Cygnus Capital Advisors’s Nurix Therapeutics NRIX Stock Holding History

Cygnus Capital Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,300
Closed -$51K – 95
2026
Q1 		$51K Buy
+3,300
New +$54.7K 0.03% 73

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cygnus Capital Advisors's NRIX Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 3,300 shares — an estimated $51K sold.

Cygnus Capital Advisors first reported a position in NRIX in Q1 2026 and held it in 1 quarter. The position peaked at $51K in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 3,300 Nurix Therapeutics shares in Q2 2026, an estimated $51K.
  • Cygnus Capital Advisors first reported a position in Nurix Therapeutics in Q1 2026 and held it in 1 quarter.
  • Cygnus Capital Advisors's Nurix Therapeutics position peaked at $51K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.